

Table S2. Summary of the demographic data, clinical features, investigations and treatment outcomes of patients with neuralgia amyotrophy after COVID-19 vaccination

Ref. no.	Age/Sex	Vaccine type (dose)	Interval between NA symptom onset and last vaccine dose (latency), days	Medical history	Clinical features	Clinical examination findings	Timing of NCS in relation to neurological symptom onset, days	NCS/EMG findings	MRI brachial plexus findings	Treatment	Outcome
1	49/M	Pfizer-BioNTech BNT162b 2 (1)	0.5	Treated Lyme disease	Left forearm neuropathic pain	Left forearm atrophy, weakness of pronation and wrist flexion	56	Isolated AIN	Denervation oedema of pronator teres, flexor carpi radialis	Conservative (NSAIDs)	Increased weakness and residual pain Follow-up: 3 months
1	44/M	Moderna MRNA-1273 (2)	18	-	Left deltoid pain	Weakness of shoulder abduction, external rotation. Reduced sensation over radial distribution	26	Upper trunk involvement	Suprascapular nerve oedema with oedema pattern of denervation of supra- and infraspinatus muscles	Conservative (Gabapentin and Physiotherapy)	Improved range of motion but not back to baseline Follow-up: 9.4 weeks
2	50/M	Pfizer-BioNTech BNT162b 2 (1)	25	-	Neuropathic pain and numbness	Weakness and numbness of arm and lateral forearm	10 and 31	Normal	Oedema and enhancement of brachial plexus	Steroid	Improved Follow-up: 7 weeks
2	44/M	Pfizer-BioNTech BNT162b 2 (2)	4	-	Neck and posterior shoulder pain. Neuropathic pain. Medial forearm/hand numbness and weakness	Right medial forearm numbness and weakness of hand	15 and 42	Lower trunk brachial plexus involvement	Oedema and enhancement of posterior scalene muscle	Conservative	Improved Follow-up: 8 weeks
2	58/M	Moderna MRNA-1273 (2)	7	-	Upper limb neuropathic pain. Shoulder pain. Distal hand weakness and numbness	Left hand weakness and numbness	35	Lower trunk brachial plexus involvement	Lower trunk brachial plexus involvement	Steroid	Improved Follow-up: 5 weeks
3	66/F	Pfizer-BioNTech BNT162b 2 (2)	14	-	Right shoulder pain and weakness. Finger numbness	Winging of scapula, weakness and pain on ROM	Not reported	Isolated long thoracic nerve involvement	Not reported	Conservative (physiotherapy)	Resolved Follow-up: 10 weeks

4	35/F	Pfizer-BioNTech BNT162b 2 (1)	9	-	Left arm weakness, numbness and paraesthesia	Left upper limb weakness and numbness	42	Upper trunk involvement	Not done	Steroids	Improved weakness and resolved numbness Follow-up: 6 weeks
5	50/M	Pfizer-BioNTech BNT162b 2 (2)	7	-	Left finger extension and hand grip weakness without pain on 2 nd dose	Left upper limb weakness	4	Predominantly lower trunk	Normal	Steroids	Partial improvement of pain and weakness Follow-up: 5 weeks

AIN: anterior interosseous nerve; EMG: electromyography; F: female; M: male; MRI: magnetic resonance imaging; NCS: nerve conduction study; NSAIDs: non-steroidal anti-inflammatory drugs; Ref: reference; ROM: range of motion

REFERENCES

1. Queler SC, Towbin AJ, Milani C, Whang J, Sneag DB. Parsonage-Turner Syndrome Following COVID-19 Vaccination: MR Neurography. *Radiology*. 2022;302(1):84-87. doi:10.1148/radiol.2021211374
2. Koh JS, Goh Y, Tan BY, et al. Neuralgic amyotrophy following COVID-19 mRNA vaccination. *QJM*. 2021;114(7):503-505. doi:10.1093/qjmed/hcab216.
3. Coffman JR, Randolph AC, Somerson JS. Parsonage-Turner Syndrome After SARS-CoV-2 BNT162b2 Vaccine: A Case Report. *JBJS Case Connect*. 2021;11(3):10.2106/JBJS.CC.21.00370. Published 2021 Sep 24. doi:10.2106/JBJS.CC.21.00370
4. Diaz-Segarra N, Edmond A, Gilbert C, McKay O, Kloeping C, Yonclas P. Painless idiopathic neuralgic amyotrophy after COVID-19 vaccination: A case report [published online ahead of print, 2021 Apr 22]. *PM R*. 2021;10.1002/pmrj.12619. doi:10.1002/pmrj.12619.
5. Mahajan S, Zhang F, Mahajan A, Zimnowodzki S. Parsonage Turner syndrome after COVID-19 vaccination. *Muscle Nerve*. 2021;64(1):E3-E4. doi:10.1002/mus.27255.